# Solu

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/solu

- Industry: Biotechnology
- Headquarters: US
- Website: www.solu.bio
- Total disclosed funding: $1.1M
- Latest round: Seed (Jun 15, 2023)
- Investors on record: 2

## About

Founded in 2022 by Sam Sihvonen (CEO), Timo Moilanen, and Kerkko Visuri, and based in Delaware, US, Solu Healthcare, Inc, doing business as Solu, operates as a biotechnology company that focuses on the research and development of antibiotic resistance prevention and detection drugs. In June 2023, Solu raised EUR 1 million in seed funding led by new investor Lifeline Ventures, with participation from another new investor Wave Ventures.



The firm employs genome sequencing methodology building a bacterial DNA library to study pathogens and analyze, monitor, and control antibiotic-resistant bacteria. The firm also develops software to understand, detect, and prevent the spread of antibiotic resistance and develop new treatment methods against resistant bacteria. 



The company intends to use the June 2023 funding to support the commercialization and development of its products.

## Funding rounds

- Seed, Jun 15, 2023, $1.1M — Lifeline Ventures, Wave Ventures

## Investors

- Lifeline Ventures (https://capitalatlas.ai/funds/lifeline-ventures) — Seed
- Wave Ventures — Seed